2-chloro-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine
• 英文别名: 2-chloro-N-(oxolan-2-ylmethyl)quinazolin-4-amine
• 化学式: C₁₃H₁₄ClN₃O
• 分子量: 263.727
• InChiKey: YYHRBGVHJGQOGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氨基-2-氟苯酚 、 2-chloro-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 0.33h， 以79%的产率得到2-fluoro-4-(4-((tetrahydrofuran-2-yl)methylamino)quinazolin-2-ylamino)phenol hydrochloride
  参考文献：
  名称：

  Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach

  摘要：

  The tyrosine kinase ACK1, a critical signal transducer regulating survival of hormone-refractory cancers, is an important therapeutic target, for which there are no selective inhibitors in clinical trials to date. This work reports the discovery of novel and potent inhibitors for ACK1 tyrosine kinase (also known as TNK2) using an innovative fragment-based approach. Focused libraries were designed and synthesized by selecting fragments from reported ACK inhibitors to create hybrid structures in a mix and match process. The hybrid library was screened by enzyme-linked immunosorbent assay-based kinase inhibition and P-33 HotSpot assays. Systematic structure-activity relationship studies led to the identification of compound (R)-9b, which shows potent in vitro (IC50 = 56 nM, n = 3, P-33 HotSpot assay) and in vivo (IC50 < 2 mu M, human cancer cell lines) ACK1 inhibition. Both (R)-9b and (S)-9b were stable in human plasma and displayed a long half-life (t(1/2) > 6 h).

  DOI：

  10.1021/jm501929n
• 作为产物：
  描述：

  2,4-喹唑啉二酮 在 sodium acetate 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 生成 2-chloro-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine
  参考文献：
  名称：

  一系列N 2，N 4-双取代的喹唑啉-2,4-二胺类的抗菌活性

  摘要：

  合成了一系列N 2，N 4-二取代的喹唑啉-2,4-二胺，并测试了其对多药耐药的金黄色葡萄球菌的抵抗力。进行了结构-活性和结构-性质关系研究，以鉴定新的命中化合物。这项研究导致N 2，N 4的鉴定-二取代的喹唑啉-2,4-二胺，在低微摩尔范围内具有最低抑菌浓度（MIC），此外还具有良好的物理化学性质。生物活性测试表明，即使使用低剂量方案，对这些药物的耐药性潜力有限，毒性低，体内活性高。总的来说，这些特性使该化合物系列成为未来抗菌剂开发的合适平台。

  DOI：

  10.1021/jm500039e

文献信息

• [EN] INHIBITORS OF ACK1/TNK2 TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE ACK1/TNK2
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2015021149A1

  公开（公告）日：2015-02-12

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are ihibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specifc example, compound having Formula I through IV are disclosed.

  描述了癌症治疗和抗癌化合物。特别是，披露了Ack1酪氨酸激酶的抑制剂及其在癌症治疗中的应用。还披露了筛选新的Ack1酪氨酸激酶抑制剂的方法。在具体示例中，披露了具有I至IV式的化合物。
• SAR refinement of antileishmanial N2,N4-disubstituted quinazoline-2,4-diamines
  作者：Xiaohua Zhu、Kurt S. Van Horn、Megan M. Barber、Sihyung Yang、Michael Zhuo Wang、Roman Manetsch、Karl A. Werbovetz

  DOI：10.1016/j.bmc.2015.02.020

  日期：2015.8

  previously been examined for their antileishmanial activity were evaluated for their potency and selectivity against Leishmania donovani, the causative parasite of visceral leishmaniasis. Quinazoline-2,4-diamines with aromatic substituents at both N2 and N4 exhibited potent in vitro antileishmanial activity but relatively low selectivity, while compounds substituted with small alkyl groups at either N2

  内脏利什曼病是一种被忽视的寄生虫病，在没有治疗的情况下死亡率很高。廉价，口服活性和有效的新药可能是对抗这种疾病的有用工具。我们以前表明，N 2，N 4-二取代的喹唑啉-2,4-二胺对细胞内利什曼原虫和铅化合物N 4-（呋喃-2-基甲基）-N 2-异丙基-7表现出低至亚微摩尔的效价。-甲基喹唑啉-2,4-二胺（4）在内脏利什曼病的急性小鼠模型中显示适度的功效。在本工作中，31 N 2，N评估了以前未检查过抗霉菌活性的4-二取代喹唑啉-2,4-二胺对内脏利什曼病的致病性寄生虫利什曼原虫的效力和选择性。在N 2和N 4处均具有芳族取代基的喹唑啉2,4-二胺显示出有效的体外抗菌活性，但选择性相对较低，而在N 2或N 4处被小烷基取代的化合物通常显示出较低的抗菌活性，但较少对鼠巨噬细胞系有毒。根据他们的体外抗农杆菌效力，N 4选择-苄基-N 2-（4-氯苄基）喹唑啉-2,4-二胺（15）和N 2-苄基-N
• INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20160176826A1

  公开（公告）日：2016-06-23

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.

  本文描述了癌症治疗和抗癌化合物。特别地，揭示了Ack1酪氨酸激酶抑制剂及其在癌症治疗中的应用。还披露了筛选新的Ack1酪氨酸激酶抑制剂的方法。具体例子中，揭示了具有I至IV式的化合物。
• Inhibitors of ACK1/TNK2 tyrosine kinase
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US10017478B2

  公开（公告）日：2018-07-10

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.

  所述的是癌症疗法和抗癌化合物。 特别是公开了 Ack1 酪氨酸激酶的抑制剂及其在治疗癌症中的用途。 还公开了筛选新的Ack1酪氨酸激酶抑制剂的方法。 在具体实例中，公开了具有式I至式IV的化合物。
• Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
  作者：Sung J. Lee、Yoshitaka Konishi、Dingwei T. Yu、Tamara A. Miskowski、Christopher M. Riviello、Orest T. Macina、Manton R. Frierson、Kigen Kondo、Masafumi Sugitani

  DOI：10.1021/jm00018a014

  日期：1995.9

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.